GLSHQ (Gelesis Holdings) EBITDA Margin %: -456.19% (As of Jun. 2023)

What is Gelesis Holdings EBITDA Margin %?

Gelesis Holdings GLSHQ -99.00% EBITDA Margin % is -456.19% as of Jun. 2023.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Gelesis Holdings's EBITDA for the three months ended in Jun. 2023 was $-5.05 Mil. Gelesis Holdings's Revenue for the three months ended in Jun. 2023 was $1.11 Mil. Therefore, Gelesis Holdings's EBITDA margin for the quarter that ended in Jun. 2023 was -456.19%.

Gelesis Holdings (OTCPK:GLSHQ) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Gelesis Holdings EBITDA Margin % Related Terms

Gelesis Holdings EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Gelesis Holdings's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gelesis Holdings EBITDA Margin % Chart

Gelesis Holdings Annual Data

Trend

Dec21

Dec22

EBITDA Margin %

-788.33

-189.47

Gelesis Holdings Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
EBITDA Margin %	Get a 7-Day Free Trial					-126.38	-191.30	-790.49	-94.87	-456.19

GLSHQ vs RBSH, PPCB, RGMP: EBITDA Margin % Comparison

For the Biotechnology subindustry, Gelesis Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gelesis Holdings EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gelesis Holdings's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Gelesis Holdings's EBITDA Margin % falls into.

Save Embed

Gelesis Holdings EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Gelesis Holdings's EBITDA Margin % for the fiscal year that ended in Dec. 2022 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-48.821	/	25.767
	=	-189.47 %

Gelesis Holdings's EBITDA Margin % for the quarter that ended in Jun. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	-5.05	/	1.107
	=	-456.19 %

Frequently Asked Questions Learn more about EBITDA Margin % →

What does a EBITDA Margin % of -456.19% mean?

Gelesis Holdings (GLSHQ) has a EBITDA Margin % of -456.19% as of Jun. 2023. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Gelesis Holdings and its competitors.

Is Gelesis Holdings' EBITDA Margin % too high?

Gelesis Holdings' current EBITDA Margin % is -456.19%.

How does Gelesis Holdings' EBITDA Margin % compare to RBSH and PPCB?

Gelesis Holdings' EBITDA Margin % of -456.19% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBITDA Margin % for a Biotechnology company?

A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBITDA Margin % mean?

A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Gelesis Holdings and its competitors. Gelesis Holdings's current EBITDA Margin % is -456.19%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Gelesis Holdings stock overvalued right now?

Gelesis Holdings (GLSHQ) has a current EBITDA Margin % of -456.19%. The current EBITDA Margin % is -456.19%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBITDA Margin % calculated?

EBITDA Margin % is calculated from a company's financial statements. For Gelesis Holdings (GLSHQ), the current EBITDA Margin % is -456.19% as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gelesis Holdings Business Description

Industry Healthcare Biotechnology

Comparable Companies RBSH PPCB RGMP CALA ONCSQ RGIN RGTPQ RSPI MYMX HGEN OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX

Address 501 Boylston Street, Suite 6102, Boston, MA, USA, 02116

Website https://www.gelesis.com

Gelesis Holdings Inc is a biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.